Global Manufacturing

It has 8 manufacturing sites built following ICH guidelines from product design to facility construction.

It has 7 manufacturing sites in China conforming to international standards.

It has 1 manufacturing site in Germany, which is one of the largest independent manufacturing sites in Europe producing transdermal drug delivery systems.

Global R&D

The group has R&D centers in China,
the U.S. and Europe.

Its robust pipeline includes 20+ drug candidates under development in China
and 10+ drug candidates under development abroad, including the U.S., Europe and Japan.

Global Market

The group has key products in the CNS, oncology,
cardiovascular and other therapeutic areas.

From 2021 to 2024,it had a total of 13 new drugs
approved for marketing in the U.S., several European
countries, and China.

It conducts business in over 80 countries and regions around the world, including major pharmaceutical markets like China,the U.S., Europe, and Japan, as well as some fast-growing emerging markets.

Global R&D

The group has R&D centers in China, the U.S. and Europe

Its robust pipeline includes 20+ drug candidates under development in China and 10+ drug candidates under development abroad, including the U.S., Europe, and Japan.

Global Manufacturing

It has 8 manufacturing sites built following ICH guidelines from product design to facility construction.

It has 7 manufacturing site in China conforming to international standards.

It has 1 manufacturing site in Germany, which is one of the largest independent manufacturing sites in Europe producing transdermal drug delivery systems.

Global Market

The group has key products in the CNS, oncology, cardiovascular and other therapeutic areas.

From 2021 to 2024, it had a total of 13 new drugs approved for marketing in the U.S., several European countries, and China.

It conducts business in over 80 countries and regions around the world, including major pharmaceutical markets like China, the U.S., Europe and Japan, as well as some fast-growing emerging markets

Culture

Mission

Advanced Technologies for
Better Quality of Life

Vision

To Be a Leading Global
Pharmaceutical Company

Business Philosophy

Customer Focus, Operational Excellence, Employee Development

Core Values

Integrity, Cooperation, Innovation, Excellence

History

1994-2010
+
  • 1994
    The establishment of Luye Pharma
  • 1998
    Established Intellectual Property Dept. and International Cooperation Dept. to pursue international development
  • 1999

    Established an R&D Center, systematically building drug research and development capabilities

    The new GMP standard plant started operations, employing an international quality management system

  • 2007
    Acquired Nanjing Kanghai, Nanjing Sike and Beijing WBL Peking University Biotech, strengthening the oncology and cardiovascular portfolios
2011-2016
+
  • 2011

    Acquired Sichuan Baoguang, strengthening its business in the endocrine and metabolism fields

  • 2013

    Topical/Oral Preparation Workshop passed EU GMP inspections

    Multiple new drugs in the CNS field were registered and undergoing clinical trials in the U.S., to drive the global R&D strategy

  • 2014
    Listed on the main board of the Hong Kong Stock Exchange, speeding up the global strategy
  • 2016

    Acquired the transdermal drug delivery system business of a Swiss pharmaceutical company Acino, expanding operations to major international markets including Europe and the U.S.

2017-2024
+
  • 2018

    Acquired AstraZeneca's Seroquel and Seroquel XR in 51 countries and regions, accelerating the creation of a global commercial network

  • 2019

    Collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets

    Licensed by PharmaMar to develop Lurbinectedin in China, enabling Chinese patients to benefit from this innovative therapy

  • 2020
    Acquired Boan, accelerating development in the field of biopharmaceuticals
  • 2021
    Began to reap the benefits of R&D with the approval of Ruiketuo (risperidone microspheres for injection (II)) and Boyounuo (bevacizumab injection) in China, and Rivastigmine Twice Weekly Transdermal Patch in several European countries.
  • 2022

    Boan Biotech was listed on the Main Board of the Hong Kong Stock Exchange, accelerating its journey towards becoming a leading global biopharmaceutical company.

    Ruoxinlin (toludesvenlafaxine hydrochloride sustained-release tablets) and Boyoubei (denosumab injection 60mg) were approved for marketing in China.

  • 2023
    Four investigational drugs were approved for marketing, including Rykindo (risperidone) for extended-release injectable suspension in the U.S., Baituowei (goserelin microspheres for injection) in China, and Lurbinectedin in China’s Hong Kong SAR and Macao SAR.
  • 2024
    Six investigational drugs were approved for marketing, including Boluojia (denosumab injection 120mg), Meibirui (paliperidone palmitate injection), Jinyouping (rotigotine microspheres for injection), Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) were approved for marketing in China; Erzofri  (paliperidone palmitate) extended-release injectable suspension  was approved for marketing in the U.S.

History

1994-2010
+
  • 1994The establishment of Luye Pharma
  • 1998Established Intellectual Property Dept. and International Cooperation Dept. to pursue international development
  • 1999Established an R&D Center, systematically building drug research and development capabilities
    The new GMP standard plant started operations, employing an international quality management system
  • 2007Acquired Nanjing Kanghai, Nanjing Sike and Beijing WBL Peking University Biotech, strengthening the oncology and cardiovascular portfolios
2011-2016
+
  • 2011

    Acquired Sichuan Baoguang, strengthening its business in the endocrine and metabolism fields

  • 2013

    Topical/Oral Preparation Workshop passed EU GMP inspections

    Multiple new drugs in the CNS field were registered and undergoing clinical trials in the U.S., to drive the global R&D strategy

  • 2014Listed on the main board of the Hong Kong Stock Exchange, speeding up the global strategy
  • 2016

    Acquired the transdermal drug delivery system business of a Swiss pharmaceutical company Acino, expanding operations to major international markets including Europe and the U.S.

2017-2024
+
  • 2018

    Acquired AstraZeneca's Seroquel and Seroquel XR in 51 countries and regions, accelerating the creation of a global commercial network

  • 2019

    Collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets

    Licensed by PharmaMar to develop Lurbinectedin in China, enabling Chinese patients to benefit from this innovative therapy

  • 2020Acquired Boan, accelerating development in the field of biopharmaceuticals
  • 2021Began to reap the benefits of R&D with the approval of Ruiketuo (risperidone microspheres for injection (II)) and Boyounuo (bevacizumab injection) in China, and Rivastigmine Twice Weekly Transdermal Patch in several European countries.
  • 2022

    Boan Biotech was listed on the Main Board of the Hong Kong Stock Exchange, accelerating its journey towards becoming a leading global biopharmaceutical company.

    Ruoxinlin (toludesvenlafaxine hydrochloride sustained-release tablets) and Boyoubei (denosumab injection 60mg) were approved for marketing in China.

  • 2023Four investigational drugs were approved for marketing, including Rykindo (risperidone) for extended-release injectable suspension in the U.S., Baituowei (goserelin microspheres for injection) in China, and Lurbinectedin in China’s Hong Kong SAR and Macao SAR.
  • 2024Six investigational drugs were approved for marketing, including Boluojia (denosumab injection 120mg), Meibirui (paliperidone palmitate injection), Jinyouping (rotigotine microspheres for injection), Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) were approved for marketing in China; Erzofri  (paliperidone palmitate) extended-release injectable suspension  was approved for marketing in the U.S.

Responsibility

We are dedicated to becoming a leading global pharmaceutical company. We have both clear business goals and ambitious social objectives as part of the vision we want to realize. We are concerned about the environment, support education, encourage innovation, care about patients and serve the community. We aim to actively fulfill our corporate social responsibility and serve the community wholeheartedly while doing business.